The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors.
 
Irene Brana
Consulting or Advisory Role - Achilles Therapeutics; Cancer Expert Now; eTheRNA Immunotherapies; Merck Sharp & Dohme; Rakuten Medical; Sanofi
Speakers' Bureau - Bristol-Myers Squibb; Merck Serono; Roche
Research Funding - AstraZeneca; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Gliknik; Janssen Oncology; Kura Oncology; Merck Sharp & Dohme; Nanobiotix; Novartis; Orion; Pfizer; Roche; Seagen (Inst); Shattuck Labs
Travel, Accommodations, Expenses - AstraZeneca Spain; Merck Serono
 
Geoffrey Shapiro
Consulting or Advisory Role - Almac Diagnostics; Angiex; Artios; Astex Pharmaceuticals; Atrin Pharmaceuticals; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Concarlo; Cybrexa Therapeutics; CytomX Therapeutics; Daiichi Sankyo; Fusion Pharmaceuticals; G1 Therapeutics; Ipsen; Lilly; Merck Serono; Pfizer; Roche; Seagen; Sierra Oncology; Syros Pharmaceuticals; Zentalis
Research Funding - Aileron Therapeutics (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CanBas (Inst); Cellceutix (Inst); Clovis Oncology (Inst); Covidien (Inst); Curis (Inst); Cyclacel (Inst); Esperas Pharma (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PTC Therapeutics (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Sierra Oncology (Inst); Syros Pharmaceuticals (Inst); Tensha Therapeutics (Inst); Tesaro (Inst); Vertex (Inst)
Patents, Royalties, Other Intellectual Property - Patent #: 9872874 Title: Dosage regimen for sapacitabine and seliciclib Issue Date: 1/23/2018; Provisional Patent #:62/538,319 Title: Compositions and methods for predicting response and resistance to CDK4/6 inhibition Filed: 7/28/17
Travel, Accommodations, Expenses - Bayer; Bicycle Therapeutics; G1 Therapeutics; Lilly; Pfizer; Sierra Oncology
 
Melissa Lynne Johnson
Consulting or Advisory Role - Abbvie (Inst); Achilles Therapeutics (Inst); Amgen (Inst); Association of Community Cancer Centers (ACCC) (Inst); Astellas Pharma (I); AstraZeneca (Inst); Atreca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Checkpoint Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Incyte (Inst); Janssen Oncology (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Otsuka (I); Pfizer (Inst); Ribon Therapeutics (Inst); Sanofi (Inst); WindMIL (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Amgen (Inst); Apexigen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Artios (Inst); AstraZeneca (Inst); Atreca (Inst); BeiGene (Inst); BerGenBio (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Checkpoint Therapeutics (Inst); Corvus Pharmaceuticals (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dracen (Inst); Dynavax Technologies (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Hengrui Pharmaceutical (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kadmon (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neovia Oncology (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); PMV Pharma (Inst); Regeneron (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); Silicon Therapeutics (Inst); Stem CentRx (Inst); Syndax (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TCR2 Therapeutics (Inst); Tmunity Therapeutics, Inc. (Inst); University of Michigan (Inst); WindMIL (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech; Incyte; Merck; Pfizer; Sanofi
 
Helena Alexandra Yu
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Daiichi Sankyo; Janssen
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Cullinan Oncology (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Lilly
Other Relationship - Astellas Pharma
 
Debbie Robbrecht
Honoraria - Springer
Consulting or Advisory Role - Cantargia AB; Faron Pharmaceuticals; Servier (Inst)
 
Daniel Shao-Weng Tan
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Loxo; Merck; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer; Roche
 
Lillian L. Siu
Leadership - Treadwell Therapeutics (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - Arvinas; AstraZeneca/MedImmune; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Janpix; Loxo; Merck; Mirati Therapeutics; MorphoSys; Navire; Oncorus; Relay Therapeutics; Roche; Seagen; Symphogen; Treadwell Therapeutics; Voronoi Health Analytics
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVID Radiopharmaceuticals (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Intensity Therapeutics (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Shattuck Labs (Inst); Symphogen (Inst)
 
Hironobu Minami
Honoraria - Abbvie; Bayer; Bristol-Myers Squibb Japan; Celgene; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - Astellas Pharma (Inst); Bayer Schering Pharma (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Mitsubishi Tanabe Pharma (Inst); MSD (Inst); Nihonkayaku (Inst); Nippon Shinyaku (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Teijin Pharma (Inst)
 
Neeltje Steeghs
Consulting or Advisory Role - AIMM Therapeutics (Inst); Boehringer Ingelheim (Inst); Ellipses Pharma (Inst)
Research Funding - AB Science (Inst); Abbvie (Inst); Actuate Therapeutics (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Cantargia AB (Inst); Cytovation (Inst); Deciphera (Inst); Genentech (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte (Inst); InteRNA (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Thomas Hengelage
Employment - Novartis
Stock and Other Ownership Interests - Novartis; Novartis (I)
 
Eugene Tan
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Kelly Biette
Employment - Novartis Institutes for BioMedical Research
 
Kun Xu
Employment - Novartis
 
Susan Elizabeth Moody
Employment - Novartis Institutes for BioMedical Research
Stock and Other Ownership Interests - Novartis
Consulting or Advisory Role - Dominion Diagnostics (I)
Patents, Royalties, Other Intellectual Property - I am named on several Novartis patents. (Inst)
Travel, Accommodations, Expenses - Dominion Diagnostics (I)
 
Maria Jove
Speakers' Bureau - MSD; Roche
Travel, Accommodations, Expenses - MSD; Roche